All News
Filter News
Found 100 articles
-
Prelude Therapeutics Announces Appointment of Martin Babler to its Board of Directors
7/19/2021
Prelude Therapeutics Inc., a clinical-stage precision oncology company, announced the appointment of Martin Babler to its Board of Directors.
-
Neoleukin Therapeutics to Participate in Jefferies Virtual Healthcare Conference
5/26/2021
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 10:30 a.m. Eastern Time.
-
Neoleukin Therapeutics Announces First Quarter 2021 Financial Results and Corporate Update
5/12/2021
Neoleukin Therapeutics, Inc., “Neoleukin”, a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, announced financial results for the quarter ending March 31, 2021 and provided a corporate update.
-
Neoleukin Therapeutics Announces Initiation of Phase 1 NL-201 Trial – Trial Evaluating NL-201 in Patients with Advanced Solid Tumors Underway –
5/5/2021
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced dosing the first patient in a Phase 1 trial of NL-201 for advanced solid tumors. NL-201 is a de novo protein designed to mimic the therapeutic activity of natural cytokines IL-2 and IL-15.
-
Neoleukin Therapeutics to Participate in BofA Securities 2021 Healthcare Conference
5/4/2021
Neoleukin Therapeutics, Inc., “Neoleukin”, a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, announced that Jonathan Drachman, M.D., Chief Executive Officer, will participate in a fireside chat during the BofA Securities 2021 Healthcare Conference on Wednesday, May 12, 2021 at 10:15 a.m. Eastern Time.
-
Clinical Catch-Up: April 26-30
5/3/2021
Although clinical trial news related to COVID-19 was slow last week, there’s quite a bit of news on studies for other indications. -
Neoleukin Therapeutics Announces Appointment of Priti Patel, M.D., M.S., as Chief Medical Officer
5/3/2021
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the appointment of Priti Patel, M.D., M.S., as Chief Medical Officer. Dr. Patel joins Neoleukin from AstraZeneca, where she served as Vice President, Head of Hematology Clinical Development since 2019.
-
Neoleukin Therapeutics Announces Clearance to Proceed with NL-201 Phase 1 Clinical Trial in the United States
4/26/2021
Neoleukin Therapeutics, Inc., “Neoleukin”, a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, announced that the U.S. Food and Drug Administration has removed the clinical hold related to its Investigational New Drug Application to begin a Phase 1 clinical program of its immunotherapeutic candidate, NL-201.
-
Neoleukin Therapeutics Announces Year End 2020 Financial Results
3/25/2021
- Anticipating first patient for NL-201 Phase 1 Trial in 1H21 - - Cash and cash equivalents of $192.6 million expected to fund operations into 2023 - - Company to host Conference Call Today, March 25, 2021 at 1:30 p.m. Pacific / 4:30 p.m. Eastern -
-
Neoleukin Therapeutics to Host 2020 Financial Results Conference Call and Webcast on March 25, 2021
3/18/2021
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced it will report full year 2020 financial results on Thursday, March 25, 2021 after the close of financial markets and then host a conference call and live audio webcast to discuss these results and provide a corporate update.
-
Neoleukin Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference
3/2/2021
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will present a corporate overview during the H.C. Wainwright Global Life Sciences Conference taking place March 9-10, 2021.
-
Neoleukin Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology Days
2/5/2021
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will participate in a fireside chat during the Guggenheim Healthcare Talks | 2021 Oncology Days on Friday, March 12, 2021 at 3 p.m. Eastern Time.
-
Company will need to provide a new assay to satisfy FDA before commencing Phase I trials.
-
Neoleukin Therapeutics Receives Clinical Hold Letter from U.S. FDA Related to CMC Assay Development for NL-201
1/8/2021
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that on January 7, 2021, it received a clinical hold letter from the U.S. Food and Drug Administration (FDA) related to its Investigational New Drug (IND) Application to begin a Phase 1 clinical program of its immunotherapeutic candidate, NL-201.
-
Neoleukin Therapeutics to Present at J.P. Morgan Healthcare Conference
1/7/2021
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will present at the 39 th Annual J.P. Morgan Virtual Healthcare Conference on Thursday, January 14, 2021 at 4:30 p.m. Eastern Time. A live audio webcast of the corporate presentation and question and answer ses
-
Neoleukin Therapeutics Announces Submission of Investigational New Drug Application for NL-201 De Novo Protein Immunotherapy Candidate for Cancer
12/10/2020
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the submission of an Investigational New Drug (IND) Application with the U.S. Food and Drug Administration to begin a Phase 1 clinical program of its lead immunotherapeutic candidate, NL-201
-
Neoleukin Therapeutics Announces Participation in Piper Sandler 32nd Annual Virtual Healthcare Conference
11/23/2020
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 32 nd Annual Virtual Healthcare Conference taking place December 1-3, 2020. The pre-recorded fireside chat will be accessible beginning at 10 a.m. Easter
-
Vaxart Hosting Key Opinion Leader Panel Call for Investors - Nov 16, 2020
11/16/2020
Vaxart, Inc., a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced that it will host a Key Opinion Leader panel for investors entitled “An Oral Tablet Vaccine – A Potential Global Solution to COVID-19 and Norovirus?” on Thursday, November 19, 2020 at 12pm Eastern Time.
-
Neoleukin Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference
11/11/2020
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will present at the Stifel 2020 Virtual Healthcare Conference on Tuesday, November 17, 2020 at 4:40 p.m. Eastern Time